A Single-Center, Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Cardiovascular Effects of Single Doses of Oral BIIB014 in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 05 Jun 2015
At a glance
- Drugs Vipadenant (Primary)
- Indications Parkinson's disease
- Focus Pharmacodynamics
- Sponsors Biogen Idec
- 24 Apr 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.
- 24 Apr 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 24 Dec 2009 New trial record